Final project plan for pharma JA Alectinib (Alecensa©)

This is the final project plan of the pharma JA on Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

Project Plan